Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 56 entries
Sorted by: Best Match Show Resources per page
In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.

Results in chemistry

Buitrón-González I, Aguilera-Durán G, Romo-Mancillas A.
PMID: 33520633
Results Chem. 2021 Jan;3:100094. doi: 10.1016/j.rechem.2020.100094. Epub 2020 Dec 28.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that leads to coronavirus disease (COVID-19) has put public health at risk in 2020. The spike protein (SP) in SARS-CoV-2 is primarily responsible for the attachment and entry of the virus into...

Cite
Buitrón-González I, Aguilera-Durán G, Romo-Mancillas A. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex. Results Chem. 2020;3:100094doi: 10.1016/j.rechem.2020.100094.
Buitrón-González, I., Aguilera-Durán, G., & Romo-Mancillas, A. (2021). In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex. Results in chemistry, 3100094. https://doi.org/10.1016/j.rechem.2020.100094
Buitrón-González, Ivonne, et al. "In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex." Results in chemistry vol. 3 (2021): 100094. doi: https://doi.org/10.1016/j.rechem.2020.100094
Buitrón-González I, Aguilera-Durán G, Romo-Mancillas A. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex. Results Chem. 2021 Jan;3:100094. doi: 10.1016/j.rechem.2020.100094. Epub 2020 Dec 28. PMID: 33520633; PMCID: PMC7834266.
Copy Download .nbib Format: NLM
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye.

Nanomedicine : nanotechnology, biology, and medicine

Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA.
PMID: 34775060
Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12.

Formulations on the base of an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by the inclusion of the drug into calcium phosphate (CaP)-particles in situ, followed by the covering of the particles with 5 kDa chitosan or 72 kDa...

Cite
Popova EV, Tikhomirova VE, Beznos OV, et al. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021;40:102493doi: 10.1016/j.nano.2021.102493.
Popova, E. V., Tikhomirova, V. E., Beznos, O. V., Chesnokova, N. B., Grigoriev, Y. V., Klyachko, N. L., & Kost, O. A. (2021). Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine : nanotechnology, biology, and medicine, 40102493. https://doi.org/10.1016/j.nano.2021.102493
Popova, Ekaterina V, et al. "Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102493. doi: https://doi.org/10.1016/j.nano.2021.102493
Popova EV, Tikhomirova VE, Beznos OV, Chesnokova NB, Grigoriev YV, Klyachko NL, Kost OA. Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye. Nanomedicine. 2021 Nov 12;40:102493. doi: 10.1016/j.nano.2021.102493. Epub 2021 Nov 12. PMID: 34775060.
Copy Download .nbib Format: NLM
Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2.

Frontiers in microbiology

Zhang Y, Ye T, Xi H, Juhas M, Li J.
PMID: 34777286
Front Microbiol. 2021 Oct 28;12:739684. doi: 10.3389/fmicb.2021.739684. eCollection 2021.

Deep learning significantly accelerates the drug discovery process, and contributes to global efforts to stop the spread of infectious diseases. Besides enhancing the efficiency of screening of antimicrobial compounds against a broad spectrum of pathogens, deep learning has also...

Cite
Zhang Y, Ye T, Xi H, et al. Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. Front Microbiol. 2021;12:739684doi: 10.3389/fmicb.2021.739684.
Zhang, Y., Ye, T., Xi, H., Juhas, M., & Li, J. (2021). Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. Frontiers in microbiology, 12739684. https://doi.org/10.3389/fmicb.2021.739684
Zhang, Yang, et al. "Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2." Frontiers in microbiology vol. 12 (2021): 739684. doi: https://doi.org/10.3389/fmicb.2021.739684
Zhang Y, Ye T, Xi H, Juhas M, Li J. Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2. Front Microbiol. 2021 Oct 28;12:739684. doi: 10.3389/fmicb.2021.739684. eCollection 2021. PMID: 34777286; PMCID: PMC8581544.
Copy Download .nbib Format: NLM
Analysis of vancomycin in the hindlimb vascular bed of the rat.

American journal of therapeutics

Jahr JS, Kang B, Kaye AD, Kaye A, Paxtor C, Feng CJ, Nossaman BD.
PMID: 11862223
Am J Ther. 1996 Oct;3(10):681-7. doi: 10.1097/00045391-199610000-00003.

Previously, studies have demonstrated that the effects of both a laboratory-produced vancomycin and a clinically available vancomycin were mediated, in part, by activation of both H(1) and H(2) receptors; however, other mechanisms may play a role in the vascular...

Cite
Jahr JS, Kang B, Kaye AD, et al. Analysis of vancomycin in the hindlimb vascular bed of the rat. Am J Ther. 1996;3(10):681-7doi: 10.1097/00045391-199610000-00003.
Jahr, J. S., Kang, B., Kaye, A. D., Kaye, A., Paxtor, C., Feng, C. J., & Nossaman, B. D. (1996). Analysis of vancomycin in the hindlimb vascular bed of the rat. American journal of therapeutics, 3(10), 681-7. https://doi.org/10.1097/00045391-199610000-00003
Jahr, J S, et al. "Analysis of vancomycin in the hindlimb vascular bed of the rat." American journal of therapeutics vol. 3,10 (1996): 681-7. doi: https://doi.org/10.1097/00045391-199610000-00003
Jahr JS, Kang B, Kaye AD, Kaye A, Paxtor C, Feng CJ, Nossaman BD. Analysis of vancomycin in the hindlimb vascular bed of the rat. Am J Ther. 1996 Oct;3(10):681-7. doi: 10.1097/00045391-199610000-00003. PMID: 11862223.
Copy Download .nbib Format: NLM
Copper and iron interactions with angiotensin-converting enzyme inhibitors. A study by fast-atom bombardment tandem mass spectrometry.

Rapid communications in mass spectrometry : RCM

Silva CM, Duarte MF, Mira ML, Florêncio MH, Versluis K, Heck AJ.
PMID: 10407284
Rapid Commun Mass Spectrom. 1999 Jun;13(12):1098-1103. doi: 10.1002/(SICI)1097-0231(19990630)13:12<1098::AID-RCM618>3.0.CO;2-Y.

Fast atom bombardment, combined with high-energy collision-induced tandem mass spectrometry, has been used to investigate gas-phase metal-ion interactions with captopril, enalaprilat and lisinopril, all angiotensin-converting enzyme inhibitors.Suggestions for the location of metal-binding sites are presented. For captopril, metal binding...

Cite
Silva CM, Duarte MF, Mira ML, et al. Copper and iron interactions with angiotensin-converting enzyme inhibitors. A study by fast-atom bombardment tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999;13(12):1098-1103doi: 10.1002/(SICI)1097-0231(19990630)13:12<1098::AID-RCM618>3.0.CO;2-Y.
Silva, C. M., Duarte, M. F., Mira, M. L., Florêncio, M. H., Versluis, K., & Heck, A. J. (1999). Copper and iron interactions with angiotensin-converting enzyme inhibitors. A study by fast-atom bombardment tandem mass spectrometry. Rapid communications in mass spectrometry : RCM, 13(12), 1098-1103. https://doi.org/10.1002/(SICI)1097-0231(19990630)13:12<1098::AID-RCM618>3.0.CO;2-Y
Silva, et al. "Copper and iron interactions with angiotensin-converting enzyme inhibitors. A study by fast-atom bombardment tandem mass spectrometry." Rapid communications in mass spectrometry : RCM vol. 13,12 (1999): 1098-1103. doi: https://doi.org/10.1002/(SICI)1097-0231(19990630)13:12<1098::AID-RCM618>3.0.CO;2-Y
Silva CM, Duarte MF, Mira ML, Florêncio MH, Versluis K, Heck AJ. Copper and iron interactions with angiotensin-converting enzyme inhibitors. A study by fast-atom bombardment tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999 Jun;13(12):1098-1103. doi: 10.1002/(SICI)1097-0231(19990630)13:12<1098::AID-RCM618>3.0.CO;2-Y. PMID: 10407284.
Copy Download .nbib Format: NLM
A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Frontiers in physiology

Claassen K, Willmann S, Eissing T, Preusser T, Block M.
PMID: 23404365
Front Physiol. 2013 Feb 08;4:4. doi: 10.3389/fphys.2013.00004. eCollection 2013.

The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis of cardiovascular disorders including hypertension and is one of the most important targets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model integrating this hormone circulation...

Cite
Claassen K, Willmann S, Eissing T, et al. A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system. Front Physiol. 2013;4:4doi: 10.3389/fphys.2013.00004.
Claassen, K., Willmann, S., Eissing, T., Preusser, T., & Block, M. (2013). A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system. Frontiers in physiology, 44. https://doi.org/10.3389/fphys.2013.00004
Claassen, Karina, et al. "A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system." Frontiers in physiology vol. 4 (2013): 4. doi: https://doi.org/10.3389/fphys.2013.00004
Claassen K, Willmann S, Eissing T, Preusser T, Block M. A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system. Front Physiol. 2013 Feb 08;4:4. doi: 10.3389/fphys.2013.00004. eCollection 2013. PMID: 23404365; PMCID: PMC3567458.
Copy Download .nbib Format: NLM
Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat.

International journal of analytical chemistry

Burckhardt BB, Laeer S.
PMID: 25873972
Int J Anal Chem. 2015;2015:796249. doi: 10.1155/2015/796249. Epub 2015 Mar 19.

In USA and Europe, medicines agencies force the development of child-appropriate medications and intend to increase the availability of information on the pediatric use. This asks for bioanalytical methods which are able to deal with small sample volumes as...

Cite
Burckhardt BB, Laeer S. Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat. Int J Anal Chem. 2015;2015:796249doi: 10.1155/2015/796249.
Burckhardt, B. B., & Laeer, S. (2015). Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat. International journal of analytical chemistry, 2015796249. https://doi.org/10.1155/2015/796249
Burckhardt, Bjoern B, and Laeer, Stephanie. "Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat." International journal of analytical chemistry vol. 2015 (2015): 796249. doi: https://doi.org/10.1155/2015/796249
Burckhardt BB, Laeer S. Sample Preparation and Extraction in Small Sample Volumes Suitable for Pediatric Clinical Studies: Challenges, Advances, and Experiences of a Bioanalytical HPLC-MS/MS Method Validation Using Enalapril and Enalaprilat. Int J Anal Chem. 2015;2015:796249. doi: 10.1155/2015/796249. Epub 2015 Mar 19. PMID: 25873972; PMCID: PMC4383429.
Copy Download .nbib Format: NLM
Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice.

Frontiers in molecular biosciences

Estrela GR, Wasinski F, Gregnani MF, Freitas-Lima LC, Arruda AC, Morais RL, Malheiros DM, Camara NOS, Pesquero JB, Bader M, Barros CC, Araújo RC.
PMID: 32528973
Front Mol Biosci. 2020 May 20;7:96. doi: 10.3389/fmolb.2020.00096. eCollection 2020.

Cisplatin is a highly effective chemotherapeutic agent. However, its use is limited by nephrotoxicity. Enalapril is an angiotensin I-converting enzyme inhibitor used for the treatment of hypertension, mainly through the reduction of angiotensin II formation, but also through the...

Cite
Estrela GR, Wasinski F, Gregnani MF, et al. Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice. Front Mol Biosci. 2020;7:96doi: 10.3389/fmolb.2020.00096.
Estrela, G. R., Wasinski, F., Gregnani, M. F., Freitas-Lima, L. C., Arruda, A. C., Morais, R. L., Malheiros, D. M., Camara, N. O. S., Pesquero, J. B., Bader, M., Barros, C. C., & Araújo, R. C. (2020). Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice. Frontiers in molecular biosciences, 796. https://doi.org/10.3389/fmolb.2020.00096
Estrela, Gabriel R, et al. "Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice." Frontiers in molecular biosciences vol. 7 (2020): 96. doi: https://doi.org/10.3389/fmolb.2020.00096
Estrela GR, Wasinski F, Gregnani MF, Freitas-Lima LC, Arruda AC, Morais RL, Malheiros DM, Camara NOS, Pesquero JB, Bader M, Barros CC, Araújo RC. Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice. Front Mol Biosci. 2020 May 20;7:96. doi: 10.3389/fmolb.2020.00096. eCollection 2020. PMID: 32528973; PMCID: PMC7257977.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 56 entries